- Home
- ABSI vs AURA Comparison
ABSI vs AURA Comparison
Compare ABSI & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- AURA
- Stock Information
- Founded
- ABSI 2011
- AURA 2007
- Country
- ABSI United States
- AURA United States
- Employees
- ABSI N/A
- AURA N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- AURA Health Care
- Exchange
- ABSI Nasdaq
- AURA Nasdaq
- Market Cap
- ABSI 318.2M
- AURA 360.2M
- IPO Year
- ABSI 2021
- AURA 2021
- Fundamental
- Price
- ABSI $3.12
- AURA $7.40
- Analyst Decision
- ABSI Strong Buy
- AURA Strong Buy
- Analyst Count
- ABSI 7
- AURA 4
- Target Price
- ABSI $8.57
- AURA $23.00
- AVG Volume (30 Days)
- ABSI 5.2M
- AURA 168.6K
- Earning Date
- ABSI 03-18-2025
- AURA 03-26-2025
- Dividend Yield
- ABSI N/A
- AURA N/A
- EPS Growth
- ABSI N/A
- AURA N/A
- EPS
- ABSI N/A
- AURA N/A
- Revenue
- ABSI $4,207,000.00
- AURA N/A
- Revenue This Year
- ABSI $7.92
- AURA N/A
- Revenue Next Year
- ABSI $162.34
- AURA N/A
- P/E Ratio
- ABSI N/A
- AURA N/A
- Revenue Growth
- ABSI N/A
- AURA N/A
- 52 Week Low
- ABSI $2.45
- AURA $6.63
- 52 Week High
- ABSI $6.72
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- ABSI 35.31
- AURA 42.78
- Support Level
- ABSI $3.02
- AURA $7.09
- Resistance Level
- ABSI $3.41
- AURA $7.59
- Average True Range (ATR)
- ABSI 0.43
- AURA 0.31
- MACD
- ABSI -0.24
- AURA 0.01
- Stochastic Oscillator
- ABSI 3.02
- AURA 32.98
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.